Etzer Darout Analyst Performance

Analyst at Guggenheim

Etzer Darout is a stock analyst at Guggenheim in the medical sector, covering 22 publicly traded companies. Over the past year, Etzer Darout has issued 38 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Etzer Darout's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Etzer Darout's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 57 Last 5 Years
Buy Recommendations: 75.44% 43 Buy Ratings
Companies Covered: 22 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	5.3%	3 ratings
Buy	70.2%	40 ratings
Hold	17.5%	10 ratings
Sell	7.0%	4 ratings

Out of 57 total stock ratings issued by Etzer Darout at Guggenheim, the majority (70.2%) have been Buy recommendations, followed by 17.5% Hold, 7.0% Sell, and 5.3% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
FTSV
Nov 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
FTSV
Feb 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	95.5% of companies on NASDAQ	21 companies
NYSE	4.5% of companies on NYSE	1 company

Etzer Darout, an analyst at Guggenheim, currently covers 22 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 22 companies	100.0%

Etzer Darout of Guggenheim specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 14 companies	63.6%
PHARMACEUTICAL PREPARATIONS 4 companies	18.2%
MED - DRUGS 3 companies	13.6%
MED PRODUCTS 1 company	4.5%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
MRUS Merus	9/30/2025	Reiterated Rating	$93.67	$97.00	Equal Weight
MRUS Merus	9/30/2025	Downgrade	$94.15	$97.00	Equal Weight
SRRK Scholar Rock	9/24/2025	Lower Price Target	$33.75	$44.00	Overweight
CCCC C4 Therapeutics	9/22/2025	Boost Price Target	$3.16	$10.00	Overweight
XNCR Xencor	9/17/2025	Initiated Coverage	$8.62	$6.00	Underweight
MGNX MacroGenics	9/17/2025	Initiated Coverage	$1.47	$3.00	Overweight
EXEL Exelixis	9/17/2025	Initiated Coverage	$39.14	$40.00	Equal Weight
CTMX CytomX Therapeutics	9/17/2025	Initiated Coverage	$1.96	$3.50	Overweight
ARVN Arvinas	9/17/2025	Initiated Coverage	$7.64	$16.00	Overweight
TERN Terns Pharmaceuticals	9/17/2025	Initiated Coverage	$7.30	$15.00	Overweight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
SMMT Summit Therapeutics	9/17/2025	Initiated Coverage	$18.12	$13.00	Underweight
SRRK Scholar Rock	9/17/2025	Initiated Coverage	$32.34	$45.00	Overweight
PTGX Protagonist Therapeutics	9/17/2025	Initiated Coverage	$58.59	$72.00	Overweight
MRUS Merus	9/17/2025	Initiated Coverage	$66.90	$112.00	Overweight
KYMR Kymera Therapeutics	9/17/2025	Initiated Coverage	$48.78	$60.00	Overweight
JANX Janux Therapeutics	9/17/2025	Initiated Coverage	$23.41	$47.00	Overweight
CCCC C4 Therapeutics	9/17/2025	Initiated Coverage	$3.41	$8.00	Overweight
ARVN Arvinas	9/16/2025	Upgrade	$7.61		Strong-Buy
CCCC C4 Therapeutics	9/16/2025	Initiated Coverage	$3.38	$8.00	Overweight
CTMX CytomX Therapeutics	9/16/2025	Upgrade	$1.93		Strong-Buy
EXEL Exelixis	9/16/2025	Upgrade	$40.44		Hold
JANX Janux Therapeutics	9/16/2025	Initiated Coverage	$23.46	$47.00	Overweight
KYMR Kymera Therapeutics	9/16/2025	Initiated Coverage	$48.12	$60.00	Overweight
MGNX MacroGenics	9/16/2025	Upgrade	$1.53		Strong-Buy
MRUS Merus	9/16/2025	Initiated Coverage	$68.18	$112.00	Overweight
PTGX Protagonist Therapeutics	9/16/2025	Initiated Coverage	$59.22	$72.00	Overweight
SMMT Summit Therapeutics	9/16/2025	Initiated Coverage	$18.09	$13.00	Underweight
SRRK Scholar Rock	9/16/2025	Initiated Coverage	$31.95	$45.00	Overweight
TERN Terns Pharmaceuticals	9/16/2025	Initiated Coverage	$7.40	$15.00	Overweight
XNCR Xencor	9/16/2025	Upgrade	$9.25		Strong Sell
IVA Inventiva	9/2/2025	Boost Price Target	$6.19	$13.00	Buy
SRRK Scholar Rock	8/7/2025	Lower Price Target	$34.62	$45.00	Outperform
TERN Terns Pharmaceuticals	5/13/2025	Lower Price Target	$2.93	$15.00	Outperform
VERV Verve Therapeutics	4/15/2025	Boost Price Target	$5.07	$24.00	Buy
IVA Inventiva	4/4/2025	Lower Price Target	$3.26	$9.00	Buy
ARVN Arvinas	3/12/2025	Set Price Target	$8.51	$20.00	Outperform
BNTX BioNTech	3/11/2025	Boost Price Target	$105.35	$143.00	Outperform
ARVN Arvinas	2/12/2025	Reiterated Rating	$18.88	$82.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.